Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2021-07-07 2:02 pm Purchase |
2021-07-02 | 13G | TherapeuticsMD, Inc. TXMD |
James E. Flynn | 413,256 4.900% |
413,256 (New Position) |
Filing History |
| 2021-07-02 5:08 pm Purchase |
2021-06-30 | 13D | Larimar Therapeutics, Inc. LRMR |
James E. Flynn | 5,836,243 32.940% |
686,171 (+13.32%) |
Filing History |
| 2021-07-01 4:50 pm Unchanged |
2021-06-28 | 13D | DFP Healthcare Acquisitions Corp. DFPH |
James E. Flynn | 10,460,000 36.380% |
0 (Unchanged) |
Filing History |
| 2021-06-14 5:18 pm Purchase |
2021-06-10 | 13D | HIGHCAPE CAP ACQUISITION CRP U CAPAU |
James E. Flynn | 1,400,000 1.690% |
400,000 (+40.00%) |
Filing History |
| 2021-06-03 4:49 pm Purchase |
2021-06-01 | 13G | Singular Genomics Systems, Inc. OMIC |
James E. Flynn | 304,734 12.890% |
304,734 (New Position) |
Filing History |
| 2021-05-26 3:53 pm Sale |
2021-03-22 | 13G | Lumos Pharma, Inc. LUMO |
James E. Flynn | 161,714 1.940% |
-774,577 (-82.73%) |
Filing History |
| 2021-05-26 1:48 pm Unchanged |
2021-05-25 | 13D | Larimar Therapeutics, Inc. LRMR |
James E. Flynn | 5,150,072 33.500% |
0 (Unchanged) |
Filing History |
| 2021-05-21 5:05 pm Purchase |
2021-05-21 | 13D | Larimar Therapeutics, Inc. LRMR |
James E. Flynn | 5,150,072 33.500% |
5,533 (+0.11%) |
Filing History |
| 2021-05-21 2:30 pm Purchase |
2021-05-11 | 13G | AdaptHealth Corp. AHCO |
James E. Flynn | 21,400,775 5.690% |
1,726,573 (+8.78%) |
Filing History |
| 2021-05-17 4:49 pm Purchase |
2021-05-05 | 13G | Spruce Biosciences, Inc. SPRB |
James E. Flynn | 1,419,651 6.090% |
1,419,651 (New Position) |
Filing History |
| 2021-05-07 4:56 pm Purchase |
2021-04-27 | 13G | KalVista Pharmaceuticals, Inc. KALV |
James E. Flynn | 1,806,037 7.430% |
1,806,037 (New Position) |
Filing History |
| 2021-05-04 12:33 pm Purchase |
2021-05-04 | 13G | Werewolf Therapeutics, Inc. HOWL |
James E. Flynn | 2,552,787 9.270% |
2,552,787 (New Position) |
Filing History |
| 2021-04-09 1:19 pm Purchase |
2021-03-30 | 13G | Wave Life Sciences Ltd. WVE |
James E. Flynn | 3,910,430 7.980% |
3,910,430 (New Position) |
Filing History |
| 2021-03-30 3:40 pm Purchase |
2021-03-30 | 13G | Edgewise Therapeutics, Inc. EWTX |
James E. Flynn | 3,933,137 8.270% |
3,933,137 (New Position) |
Filing History |
| 2021-03-17 11:01 am Purchase |
2021-03-15 | 13G | Xeris Biopharma Holdings, Inc. XERS |
James E. Flynn | 12,435,751 9.880% |
6,553,398 (+111.41%) |
Filing History |
| 2021-02-22 4:45 pm Unchanged |
2021-02-18 | 13D | HIGHCAPE CAP ACQUISITION CRP U CAPAU |
James E. Flynn | 1,000,000 8.400% |
0 (Unchanged) |
Filing History |
| 2021-02-12 12:41 pm Sale |
2020-12-31 | 13G | DBV Technologies S.A. DBVT |
James E. Flynn | 0 0.000% |
-118,900 (Position Closed) |
Filing History |
| 2021-02-12 12:40 pm Sale |
2020-12-31 | 13G | Alimera Sciences, Inc. ALIM |
James E. Flynn | 0 0.000% |
-676,667 (Position Closed) |
Filing History |
| 2021-02-12 12:39 pm Sale |
2020-12-31 | 13G | AVEO Pharmaceuticals, Inc. AVEO |
James E. Flynn | 0 0.000% |
-1,574,000 (Position Closed) |
Filing History |
| 2021-02-12 12:39 pm Sale |
2020-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR |
James E. Flynn | 15,250 2.730% |
-14,981 (-49.56%) |
Filing History |